Cordyceps sinensis Acts As an Adenosine A3 Receptor Agonist on Mouse Melanoma and Lung Carcinoma Cells, and Human Fibrosarcoma and Colon Carcinoma Cells

Noriko Yoshikawa; Arisa Nishiuchi; Erika Kubo; Yu Yamaguchi; Masaru Kunitomo; Satomi Kagota; Kazumasa Shinozuka; Kazuki Nakamura

doi:10.4236/pp.2011.24034

Home > Journals > Chemistry & Materials Science | Medicine & Healthcare > PP

Pharmacology & Pharmacy > Vol.2 No.4, October 2011

Cordyceps sinensis Acts As an Adenosine A₃ Receptor Agonist on Mouse Melanoma and Lung Carcinoma Cells, and Human Fibrosarcoma and Colon Carcinoma Cells ()

Noriko Yoshikawa, Arisa Nishiuchi, Erika Kubo, Yu Yamaguchi, Masaru Kunitomo, Satomi Kagota, Kazumasa Shinozuka, Kazuki Nakamura

DOI: 10.4236/pp.2011.24034 PDF HTML 4,458 Downloads 9,205 Views Citations

Abstract

Cordyceps sinensis, a parasitic fungus on the larva of Lapidoptera, has been used as a traditional Chinese medicine. We previously reported that the growth of B16-BL6 mouse melanoma (B16-BL6) cells and mouse Lewis lung carcinoma (LLC) cells was inhibited by cordycepin (3’-deoxyadenosine), an ingredient of Cordyceps sinensis, and its effect was antagonized by MRS1191, a selective adenosine A₃ receptor (A₃-R) antagonist although adenosine (up to 100 μM) had no effect on the growth of B16-BL6 and LLC cells. In this study, we investigated whether water extracts of Cordyceps sinensis (WECS) inhibit the growth of B16-BL6 cells, LLC cells, HT1080 human fibrosarcoma (HT1080) cells and CW-2 human colon carcinoma (CW-2) cells via their A₃-R. As a result, the growth of all cell lines were potently inhibited by WECS (10 μg/mL) and the inhibitory effect of WECS was significantly antagonized by MRS1191 (1 μM). Furthermore, WECS included 2.34% w/w cordycepin and 0.12% w/w adenosine as components according to the HPLC- ECD system. In conclusion, WECS inhibited the proliferation of four cancer cell lines by stimulation of A₃-R and the main component in WECS with anticancer action might be cordycepin instead of adenosine.

Keywords

Cordyceps Sinensis, Adenosine A₃ Receptor, Cordycepin, HPLC-ECD

Share and Cite:

N. Yoshikawa, A. Nishiuchi, E. Kubo, Y. Yamaguchi, M. Kunitomo, S. Kagota, K. Shinozuka and K. Nakamura, "Cordyceps sinensis Acts As an Adenosine A₃ Receptor Agonist on Mouse Melanoma and Lung Carcinoma Cells, and Human Fibrosarcoma and Colon Carcinoma Cells," Pharmacology & Pharmacy, Vol. 2 No. 4, 2011, pp. 266-270. doi: 10.4236/pp.2011.24034.

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	J. S. Zhu, G. M. Halpern and K. Jones, “The scientific rediscovery of an ancient Chinese herbal medicine: Cordyceps sinensis Part I,” Journal of Alternative and Complementary Medicine, Vol. 4, 1998, pp. 289-303.
[2]	K. Nakamura, Y. Yamaguchi, S. Kagota, Y. M. Kwon, K. Shinozuka and M. Kunitomo, “Inhibitory effect of Cordyceps sinensis on spontaneous liver metastasis of Lewis lung carcinoma and B16 melanoma cells in syngeneic mice,” Japanese Journal of Pharmacology, Vol. 79, 1999, pp. 335-341.
[3]	K. Nakamura, N. Yoshikawa, Y. Yamaguchi, S. Kagota, K. Shinozuka and M. Kunitomo, “Antitumour effect of cordycepin (3’-deoxyadenosine) on mouse melanoma and lung carcinoma cells involves adenosine A3 receptor stimulation,” Anticancer Research, Vol. 26, 2006, pp. 43-48.
[4]	Y. Yamaguchi, S. Kagota, J. Haginaka and M. Kunitomo, “Participation of peroxynitrite in oxidative modification of LDL by aqueous extracts of cigarette smoke,” FEBS Letters, Vol. 512, 2002, pp. 218-222.
[5]	J. Chen, W. Zhang, T. Lu, J. Li, Y. Zheng and L. Kong, “Morphological and genetic characterization of a cultivated Cordyceps sinensis fungus and its polysaccharide component possessing antioxidant property in H22 tumor-bearing mice,” Life Sciences, Vol. 78, 2006, pp. 2742-2748.
[6]	N. Yoshikawa, S. Yamada, C. Takeuchi, S. Kagota, K. Shinozuka, M. Kunitomo and K. Nakamura, “Cordycepin (3’-deoxyadenosine) inhibits the growth of B16-BL6 mouse melanoma cells through the stimulation of adenosine A3 receptor followed by glycogen synthase kinase-3β activation and cyclin D1 suppression,” Naunyn- Schmiedeberg’s Archives of Pharmacology, Vol. 377, 2008, pp. 591-595.